What are the various insulin preparation types and their primary clinical uses?

Types of Insulin Preparations and Their Clinical Uses

Insulin preparations are categorized into rapid-acting analogs, short-acting (regular), intermediate-acting (NPH), long-acting analogs, ultra-long-acting analogs, concentrated formulations, premixed combinations, and inhaled insulin, each designed to replicate specific phases of physiological insulin secretion. 1, 2

Rapid-Acting Insulin Analogs

These are the gold standard for prandial (mealtime) insulin coverage in both type 1 and type 2 diabetes. 3

Standard Rapid-Acting Analogs

• Insulin lispro (Humalog), aspart (Novolog), and glulisine (Apidra) have onset of action within 0.25-0.5 hours, peak at 1-3 hours, and duration of 3-5 hours 2
• These analogs provide superior postprandial glucose control compared to regular human insulin due to reduced hexamer aggregation, allowing faster subcutaneous absorption 4, 5
• Administer 15 minutes or less before meals for optimal glycemic control 6
• They reduce risk of late postprandial hypoglycemia and nocturnal hypoglycemia compared to regular insulin 5, 3

Ultra-Rapid-Acting Analogs

• Faster aspart and ultra-rapid lispro contain excipients (niacinamide, L-arginine) that accelerate absorption beyond conventional rapid-acting analogs 1, 4
• These provide even better coverage of early postprandial glucose excursions and allow more flexible meal-time dosing 7, 4

Clinical Uses

• Primary prandial insulin for all patients with type 1 diabetes on basal-bolus regimens or insulin pumps 1, 2
• Added to basal insulin in type 2 diabetes when A1C remains above target despite optimized basal insulin 6
• Typical starting dose: 4 units per meal or 0.1 units/kg per meal 6

Short-Acting (Regular) Human Insulin

• Onset 0.5-1 hour, peak 2-4 hours, duration 5-8 hours 2
• Requires administration 30 minutes before meals, making it less convenient than rapid-acting analogs 3
• U-500 regular insulin is specifically indicated for patients requiring >200 units daily, with pharmacokinetics resembling intermediate-acting insulin 8, 9
• Regular insulin has been largely replaced by rapid-acting analogs except in resource-limited settings or for U-500 formulation 10, 3

Intermediate-Acting Insulin

NPH (Neutral Protamine Hagedorn)

• Onset 2-4 hours, peak 4-8 hours, duration 12-18 hours 2
• Provides basal coverage but has pronounced peak, increasing hypoglycemia risk compared to long-acting analogs 10, 5
• Used in premixed formulations (70% NPH/30% regular) for simplified twice-daily regimens 8
• Less expensive than analogs but associated with more hypoglycemia and greater glucose variability 10

Long-Acting Basal Insulin Analogs

These provide peakless, consistent 24-hour basal insulin coverage with lower hypoglycemia risk than NPH. 10, 5

Insulin Glargine (Lantus, Basaglar, Toujeo)

• U-100 formulation: onset 2-4 hours, no peak, duration up to 24 hours 2, 9
• U-300 formulation (Toujeo): longer duration (>24 hours) with more stable coverage and lower hypoglycemia rates than U-100 8, 9
• Administered once daily at consistent time; some patients require twice-daily dosing if duration inadequate 9
• Cannot be mixed with other insulins due to acidic pH 9

Insulin Detemir (Levemir)

• Onset 2-4 hours, no peak, duration 12-24 hours 2
• Often requires twice-daily administration for full 24-hour coverage 9
• Lower intraindividual variability than NPH and glargine, potentially contributing to reduced hypoglycemia 5
• Associated with less weight gain than NPH 10

Insulin Degludec (Tresiba)

• Onset 2-4 hours, no peak, duration >24 hours (mean half-life 25.4 hours) 2, 10
• Ultra-long duration allows flexible once-daily dosing with lowest hypoglycemia rates among basal insulins 10
• U-200 formulation available for patients requiring higher doses 8

Clinical Uses

• First-line basal insulin for both type 1 and type 2 diabetes 1, 9
• Type 2 diabetes: typically start 10 units daily or 0.1-0.2 units/kg/day 9
• Type 1 diabetes: basal insulin comprises 40-60% of total daily dose in multiple daily injection regimens 1, 9
• If basal dose exceeds 0.5 units/kg/day with A1C still above target, advance to combination therapy with GLP-1 receptor agonist or add prandial insulin rather than continuing to escalate basal insulin alone 8, 9

Concentrated Insulin Formulations

These allow administration of higher doses in smaller volumes for patients with severe insulin resistance. 8

• U-200 insulin lispro and U-200 degludec: twice the concentration of standard U-100 formulations 8, 6
• U-300 glargine (Toujeo): requires approximately 10-18% higher daily dose than U-100 glargine due to modestly lower per-unit efficacy 9
• U-500 regular insulin: five times more concentrated, indicated for patients requiring >200 units/day, with intermediate-acting pharmacokinetics 8, 9
• Critical safety consideration: switching between concentrations requires medical supervision and dose adjustment to prevent fatal dosing errors 9, 11

Premixed Insulin Combinations

• Contain fixed ratios of basal and prandial insulin in single injection 8
• NPH/Regular 70/30: 70% NPH, 30% regular insulin 8
• Analog premixes: Humalog Mix 50/50, NovoMix 50 (50% rapid-acting, 50% protaminated intermediate-acting) 11

Clinical Uses

• Simplify regimens by reducing injection frequency, typically administered twice daily 8
• Major limitation: inflexible dosing that cannot independently adjust basal versus prandial components 8
• Best suited for patients with consistent meal patterns and carbohydrate intake 8

Inhaled Insulin

• Rapid-acting inhaled human insulin with onset similar to rapid-acting analogs but slightly longer duration 8, 5
• Available for prandial use with limited dosing range 8
• Absolutely contraindicated in chronic lung disease (asthma, COPD) and not recommended in current or recent smokers 8
• Requires spirometry (FEV1) testing before initiation and periodically during treatment 8
• Pilot studies suggest potential for postprandial supplemental dosing without additional hypoglycemia 8

Automated Insulin Delivery Systems

• Hybrid closed-loop systems combining continuous subcutaneous insulin infusion with continuous glucose monitoring are superior to sensor-augmented pump therapy for increasing time-in-range and reducing hypoglycemia in type 1 diabetes 1
• Should be considered for all individuals with type 1 diabetes whenever feasible 1

Critical Clinical Caveats

Combination Therapy Principles

• When basal insulin optimized to acceptable fasting glucose but A1C remains elevated, adding GLP-1 receptor agonist provides potent glucose-lowering with less weight gain and hypoglycemia than intensifying insulin alone 8, 9
• Continue metformin when initiating or intensifying insulin therapy 6

Common Pitfalls

• Overbasalization: continuing to escalate basal insulin beyond 0.5 units/kg/day without adding prandial coverage leads to increased hypoglycemia without A1C improvement 9
• Mixing insulins: glargine cannot be mixed with other insulins; when both basal and prandial insulin needed, administer as separate injections 9
• Biosimilar substitution: Basaglar and Semglee are interchangeable with reference glargine products when unavailable 9
• Formulation switches: U-100 to U-300 glargine or other concentration changes require medical supervision and are not unit-for-unit interchangeable 9

Special Populations

• Puberty: insulin requirements may increase to 1.5 units/kg/day due to growth hormone and sex hormone effects 9
• Elderly hospitalized patients with reduced intake: start with reduced dose of 0.1-0.15 units/kg/day, primarily as basal insulin 9